{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-23-000043","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.785385+00:00","generated_at":"2026-06-16T01:09:03.182480+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LivaNova Q1 revenue up 9.7% to $263M, EPS $0.14, raises 2023 guidance; names interim CEO","bullets":["Revenue $263.4M, +9.7% reported (+12.7% constant currency) vs. prior year.","GAAP diluted EPS $0.14; adjusted diluted EPS $0.43.","Received FDA 510(k) clearance for Essenz heart-lung machine.","Randomized 500th unipolar depression patient in RECOVER study.","Bill Kozy appointed interim CEO after Damien McDonald's resignation; full-year 2023 guidance raised."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-23-000043","json":"https://secwatch.observer/filing/0001639691-23-000043.json","markdown":"https://secwatch.observer/filing/0001639691-23-000043.md","text":"https://secwatch.observer/filing/0001639691-23-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000043/0001639691-23-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000043/livn-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:09:03.182480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd02bb85685d57b426e90801bdf2e5ab1282dd1c","claim":"LivaNova PLC reported the quarter ended March 31, 2023 results: revenue $263.4 million, net income $0.14 per share, EPS $0.14. Guidance raised.","evidence_excerpt":"innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights 1 • First-quarter revenue of $263.4 million increased 9.7 percent on a reported basis and increased 12.7 percent on a constant-currency basis, as compared to the prior-year period • First-quarter U.S. GAAP diluted earnings","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000043/0001639691-23-000043-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$263.4 million"},{"label":"Net income","value":"$0.14 per share"},{"label":"EPS","value":"$0.14"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}